Your browser doesn't support javascript.
loading
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.
Bowtell, David D; Böhm, Steffen; Ahmed, Ahmed A; Aspuria, Paul-Joseph; Bast, Robert C; Beral, Valerie; Berek, Jonathan S; Birrer, Michael J; Blagden, Sarah; Bookman, Michael A; Brenton, James D; Chiappinelli, Katherine B; Martins, Filipe Correia; Coukos, George; Drapkin, Ronny; Edmondson, Richard; Fotopoulou, Christina; Gabra, Hani; Galon, Jérôme; Gourley, Charlie; Heong, Valerie; Huntsman, David G; Iwanicki, Marcin; Karlan, Beth Y; Kaye, Allyson; Lengyel, Ernst; Levine, Douglas A; Lu, Karen H; McNeish, Iain A; Menon, Usha; Narod, Steven A; Nelson, Brad H; Nephew, Kenneth P; Pharoah, Paul; Powell, Daniel J; Ramos, Pilar; Romero, Iris L; Scott, Clare L; Sood, Anil K; Stronach, Euan A; Balkwill, Frances R.
Afiliação
  • Bowtell DD; Cancer Genomics and Genetics Program, Peter MacCallum Cancer Centre, Melbourne, Victoria 8006, Australia; and the Kinghorn Cancer Centre, Garvan Institute for Medical Research, Darlinghurst, Sydney, 2010 New South Wales, Australia.
  • Böhm S; Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M6BQ, UK.
  • Ahmed AA; Nuffield Department of Obstetrics and Gynaecology and the Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford OX3 9DS, UK.
  • Aspuria PJ; Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, California 90048, USA.
  • Bast RC; MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030-4009, USA.
  • Beral V; University of Oxford, Headington, Oxford, OX3 7LF, UK.
  • Berek JS; Stanford University, Stanford, California 94305, USA.
  • Birrer MJ; Massachusetts General Hospital, Boston, Massachusetts 02114 USA.
  • Blagden S; Ovarian Cancer Action Research Centre, Imperial College London, Hammersmith Campus, London W12 0NN, UK.
  • Bookman MA; Arizona Oncology, Tucson, Arizona 85711, USA.
  • Brenton JD; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge CB2 0RE, UK.
  • Chiappinelli KB; The Sidney Kimmel Cancer Center at John Hopkins University, Baltimore, Maryland 21287, USA.
  • Martins FC; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge CB2 0RE, UK.
  • Coukos G; University Hospital of Lausanne, Lausanne, Switzerland.
  • Drapkin R; University of Pennsylvania, Penn Ovarian Cancer Research Center, Philadelphia, Pennsylvania 19104, USA.
  • Edmondson R; University of Manchester, Manchester M13 9WL, UK.
  • Fotopoulou C; Ovarian Cancer Action Research Centre, Imperial College London, Hammersmith Campus, London W12 0NN, UK.
  • Gabra H; Ovarian Cancer Action Research Centre, Imperial College London, Hammersmith Campus, London W12 0NN, UK.
  • Galon J; Institut National de la Santé et de la Recherche Médicale, UMRS1138, Laboratory of Integrative Cancer Immunology, Cordeliers Research Center, Université Paris Descartes, Sorbonne Paris Cité, Sorbonne Universités, UPMC Univ Paris 06, 75006 Paris, France.
  • Gourley C; Cancer Research Centre, University of Edinburgh, Edinburgh EH4 2XR, UK.
  • Heong V; Walter and Eliza Hall Institute, Parkville, Victoria 3052, Australia.
  • Huntsman DG; University of British Columbia, Departments of Pathology and Laboratory Medicine and Obstetrics and Gynecology, Faculty of Medicine, Vancouver, British Columbia V6T 2B5, Canada.
  • Iwanicki M; Harvard Medical School, Boston, Massachusetts 02115, USA.
  • Karlan BY; Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, California 90048, USA.
  • Kaye A; Ovarian Cancer Action, London NW1 OJH, UK.
  • Lengyel E; University of Chicago, Chicago, Illinois 60637, USA.
  • Levine DA; Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
  • Lu KH; MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030-4009, USA.
  • McNeish IA; University of Glasgow, Glasgow G61 1QH, UK.
  • Menon U; Women's Cancer, Institute for Women's Health, University College London, London WC1E 6BT, UK.
  • Narod SA; Women's College Research Institute, Toronto, Ontario M5G 1N8, Canada.
  • Nelson BH; British Columbia Cancer Agency, Victoria, British Columbia V8R 6V5, Canada.
  • Nephew KP; Indiana University School of Medicine &Simon Cancer Center, Bloomington, IN 47405-4401, USA.
  • Pharoah P; University of Cambridge, Strangeways Research Laboratory, Cambridge CB1 8RN, UK.
  • Powell DJ; University of Pennsylvania, Philadelphia, PA 19104-5156, USA.
  • Ramos P; Translational Genomics Research Institute (Tgen), Phoenix, Arizona 85004, USA.
  • Romero IL; University of Chicago, Chicago, Illinois 60637, USA.
  • Scott CL; Walter and Eliza Hall Institute, Parkville, Victoria 3052, Australia.
  • Sood AK; MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030-4009, USA.
  • Stronach EA; Ovarian Cancer Action Research Centre, Imperial College London, Hammersmith Campus, London W12 0NN, UK.
  • Balkwill FR; Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M6BQ, UK.
Nat Rev Cancer ; 15(11): 668-79, 2015 Nov.
Article em En | MEDLINE | ID: mdl-26493647
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Cistadenocarcinoma Seroso Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Cistadenocarcinoma Seroso Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Ano de publicação: 2015 Tipo de documento: Article